Patients
18.4 % of people
People aged 65 and over, US, 2025 (World Bank).
Compare every country on the Public Health DashboardUS Orthobiologics Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.36 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.83 Bn | — | — |
| 2025 (base) | $2.95 Bn | +$121.5 Mn | — |
| 2026 (forecast) | $3.07 Bn | +$126.7 Mn | +4.3% |
| 2027 (forecast) | $3.21 Bn | +$132.2 Mn | +8.8% |
| 2028 (forecast) | $3.34 Bn | +$137.9 Mn | +13.5% |
| 2029 (forecast) | $3.49 Bn | +$143.8 Mn | +18.3% |
| 2030 (forecast) | $3.64 Bn | +$150.0 Mn | +23.4% |
| 2031 (forecast) | $3.79 Bn | +$156.4 Mn | +28.7% |
| 2032 (forecast) | $3.96 Bn | +$163.1 Mn | +34.3% |
| 2033 (forecast) | $4.13 Bn | +$170.2 Mn | +40% |
| 2034 (forecast) | $4.30 Bn | +$177.5 Mn | +46.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.95 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $4.30 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 4.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, application and end user (see all) |
| Key players | Medtronic, Stryker, Zimmer Biomet Holdings, Inc., Bioventus, Orthofix Medical (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Orthobiologics use natural substances such as bone grafts, growth factors and cells to help bones and soft tissue heal.
Key segments of the orthobiologics market include product (Bone Grafts, Platelet-Rich Plasma and Stem Cells) and application (Spinal Fusion, Trauma and Sports Injuries).
An ageing and more active population, more sports injuries, rising obesity and better implants and procedures are driving the orthobiologics market.
Same-day joint surgery, robotics, smart implants and biologic treatments give the orthobiologics market room to grow.
High procedure costs, pricing pressure from hospitals, recalls and long recovery times hold back the orthobiologics market.
The orthobiologics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] People aged 65 and over: 18.4% of people in 2025, the latest World Bank figure for the US.[3]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how orthobiologics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
What doctors and scientists are doing in Orthobiologics right now, from free public sources.
18.4 % of people
People aged 65 and over, US, 2025 (World Bank).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 16 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.
From our blog
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US
US
US
Digital Health · US
Pharmaceuticals · US
Pharmaceuticals · US
OTC & Nutraceuticals · US
Healthcare Services · US
Pharmaceuticals · US